MOLECULAR TEMPL Revenue, Profits - MTEM Annual Income Statement

Add to My Stocks
$4.07 $0 (0%) MTEM stock closing price Sep 17, 2018 (Closing)

Fundamental analysis of MTEM stock involves analyzing its financial statements, apart from checking the MOLECULAR TEMPL stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement for MTEM which shows a YOY revenue growth of 0 is specific to a period of time. Investors typically check YoY or QoQ revenue growth. Along with MOLECULAR TEMPL assets and MOLECULAR TEMPL free cash flow, MOLECULAR TEMPL profits as shown in profit and loss statement give key insights about the business. The net profit for 2017 is $-23.14M and the 2017 revenue is $3.39M.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
MOLECULAR TEMPL Revenues or Net Sales
3.39M-76.91M14.72M12.49M5.86M---1.44M
Cost Of Goods Sold (COGS)----------
MOLECULAR TEMPL Gross Profit
3.39M-76.91M14.72M12.49M5.86M---1.44M
Research & Development Expense9.48M16.55M40.27M35.83M29.33M18.78M24.38M18.93M15.84M13.44M
Selling General & Admin Expense11.75M7.8M9.71M10.14M9.18M7.08M5.71M4.97M5.48M6.73M
Income Before Depreciation Depletion Amortization-17.84M-24.36M26.92M-31.25M-26.02M-19.99M-30.03M-23.9M-21.32M-18.73M
Depreciation Depletion Amortization----------
Non Operating Income-4.44M-16.89M9.46M-2.18M-51.13M4.38M5.22M--
Interest Expense--------2.42M-
MOLECULAR TEMPL Pretax Income
-23.14M-24.09M43.82M-21.78M-28.21M-71.13M-25.65M-18.68M-23.64M-18.29M
Provision for Income Taxes----0.2M------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-23.14M-24.09M43.82M-21.58M-28.41M-71.13M-25.65M-18.68M-23.64M-18.29M
Extraordinary Items & Discontinued Operations----------
MOLECULAR TEMPL Profit/ Loss (Net Income)
-23.14M-24.09M43.82M-21.58M-28.41M-71.13M-25.65M-18.68M-23.64M-18.29M
Average Shares used to compute Diluted EPS11.4M6.5M6.68M5.76M5.26M4.93M4.17M3.06M1.78M-
Average Shares used to compute Basic EPS11.4M6.5M6.39M5.48M5.26M4.93M4.17M3.06M1.78M-
Income Before Nonrecurring Items-23.14M-24.22M27.02M-27.63M-13.47M-37.86M-28.51M-18.68M-23.65M-18.29M
Income from Nonrecurring Items--16.8M6.05M-14.95M-33.28M2.86M---
MOLECULAR TEMPL Earnings Per Share Basic Net
-2.11-3.746.82-3.96-5.39-14.41-6.16-6.16-13.31-21.67
MOLECULAR TEMPL Earnings Per Share Diluted Net
-2.11-3.745.94-5.39-5.39-14.41-6.16-6.16-13.31-21.67
EPS Diluted Before Nonrecurring Items-2.11-3.743.30-6.49-2.53-7.70-6.82-6.16-13.31-21.67
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on MOLECULAR TEMPL stock analysis. It helps to look at the following income statement items:

  • Topline: A growing topline, as seen from the MOLECULAR TEMPL revenue chart, as is the case with MOLECULAR TEMPL indicates a growing business. One needs to compare the YoY topline or sales growth of MTEM stock with its peers like TBUFF stock and RFL stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-23.14M for MOLECULAR TEMPL for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the MTEM income statement, one can check the MOLECULAR TEMPL historical stock prices to check how the price has moved with time.

MOLECULAR TEMPL Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
33.17
Dividend Yield
0%